Repligen Co. (NASDAQ:RGEN) Stock Holdings Lessened by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company decreased its stake in Repligen Co. (NASDAQ:RGEN) by 1.5% in the third quarter, HoldingsChannel reports. The firm owned 66,667 shares of the biotechnology company’s stock after selling 1,034 shares during the period. The Manufacturers Life Insurance Company’s holdings in Repligen were worth $9,921,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Andra AP fonden acquired a new stake in Repligen during the 2nd quarter valued at $25,000. UMB Bank n.a. lifted its position in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares during the period. International Assets Investment Management LLC purchased a new position in Repligen during the second quarter valued at approximately $33,000. Finally, nVerses Capital LLC acquired a new position in Repligen in the 3rd quarter valued at approximately $45,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on RGEN. Royal Bank of Canada reiterated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Wells Fargo & Company assumed coverage on shares of Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Finally, Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Stock Down 1.3 %

RGEN stock opened at $148.50 on Wednesday. The business’s 50-day simple moving average is $141.29 and its 200 day simple moving average is $142.10. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.32 billion, a PE ratio of -401.34, a price-to-earnings-growth ratio of 4.53 and a beta of 0.96. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the prior year, the company posted $0.23 earnings per share. Repligen’s revenue was up 9.7% on a year-over-year basis. On average, research analysts anticipate that Repligen Co. will post 1.52 earnings per share for the current year.

Insider Activity

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.